Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.

Biotechnology

Health & Wellness

Geron

John A. Scarlett

Joseph Eid

Jim Ziegler

Ryan Vincenti

Scott Hutson

Nishan Sengupta

Michelle Robertson

Scott A. Samuels

Andrew J. Grethlein

Faye Feller

Melissa A. Kelly Behrs

Edward Koval

Directors

Clinical Operations Team

Medical and Clinical Teams

Leadership Team

Business Operations Team

Human Resources Team

Vice Presidents

Research and Clinical Management

Key Account Management

Teams at Geron